Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

<a href="https://www.medindia.net/multimedia/graphics/infographics/insulin-injections-for-diabetes.htm"> <img data-src="https://www.medindia.net/images/common ...

After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management ... brings together a pre-filled insulin pen, the TempoSmart app and ...

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

This human insulin analogue that comes in disposable pens prefilled with 1, 1.5, or 3 mL, dosed in 10-unit increments1 binds reversibly to albumin, which extends its half-life to around 7 days. Steady ...

In healthy individuals, the body produces all the insulin that it needs. However, people with diabetes either don't ... Once you open a vial of insulin or pen, another expiration date starts.

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products ...